SecBot SecBot

ABVX

Abivax S.A.
Nasdaq· Pharmaceutical Preparations· Inc. I0· CIK 0001956827 Biotech & Drug Discovery
$83.61 −3.97 (−4.53%)
Nov 16 4:00 PM ET · prev $87.58
Market cap
$7.9B
Mid cap
Consensus
Buy
86% Buy or better · 14 analysts
Median target
$164.00
+96% · range $142.00–181.00
1 year
−26.4%
from $113.62 · Nov 17
30 days
−4.4%
from $87.49
52-week range
$72.50–145.31
−42% from high · low Jun 2
Avg volume 20D
778.6K
shares / day
Short interest
4.11M
≈4.7% of shares · −43.3%
Days to cover
4.6
at average volume
New fund stakes
6
Q2 2026 13F · 2 exits
Filing reports
6
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 33 added (6 new), 35 trimmed or exited. Largest new: Ra Capital Management, $150.9M, Norges Bank $146.6M.

  • AnalystsBULLISH

    12 of 14 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.673 → −$0.857 over 90 days. 1 up, 3 down in 30 days.

  • Short sellersCOVERING

    Short interest −43.3% to 4.11M shares. 4.6 days to cover, ≈4.7% of shares.

  • TrendDOWNTREND

    11% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 1.

Who's buying

13F· Q2 2026
6
new positions
2
exits
$358.1M
in new stakes
FundMoveSharesValue
UBS Group AGTRIM1,844,918$245.9M
CITADEL ADVISORS LLCDOUBLED1,438,352$191.7M
RA CAPITAL MANAGEMENT, L.P.NEW1,132,557$150.9M
NORGES BANKNEW1,100,000$146.6M
SUSQUEHANNA INTERNATIONAL GROUP, LLPDOUBLED1,053,896$140.4M
BANK OF AMERICA CORP /DE/ADD971,439$129.5M
GOLDMAN SACHS GROUP INCDOUBLED792,712$105.6M
BALYASNY ASSET MANAGEMENT L.P.DOUBLED603,840$80.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 86% rate it Buy or better
Strong Buy5Buy7Hold2Sell0Strong Sell0
12-month targets · 12 analysts

Price is below the lowest target. Median implies +96%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Oct 21, 2026Wedbush
MAINTAIN
MAINTAINNeutral
Oct 20, 2026Guggenheim
REITERATE
REITERATEBuy
Sep 22, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Sep 22, 2026Wedbush
MAINTAIN
MAINTAINNeutral
Sep 22, 2026Barclays
MAINTAIN
MAINTAINOverweight
Sep 10, 2026Goldman Sachs
INITIATE
INITIATEBuy

Earnings setup

Estimates
−$0.86
EPS estimate, this quarter
−27%
estimate change, 90 days
1↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.86-$1.11–-$0.59-12.3%$676.4K
Next Q-$0.89-$1.16–-$0.64-15.9%$686.0K
Current FY-$4.17-$4.67–-$3.81-16.5%$4.0M
Next FY-$3.84-$4.91–-$2.52-14.7%$71.9M
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.

Short side

FINRA· Oct 30, 2026
4,110,784
shares short
-43.3%
vs prior settlement
4.6
days to cover
≈4.7%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 2, 2026
Press release
Abivax to Participate in Upcoming Fall Investor Conferences
Abivax to Participate in Upcoming Fall Investor Conferences
Oct 30, 2026
Short interest
Short Interest: ABVX down 43% to 4.1M shares
Settlement 2026-10-30 | Days to cover: 4.63 | ≈4.71% of shares outstanding (est.)
Sep 30, 2026
Press release
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Sep 29, 2026
Clinical Trial
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Phase 2 · COMPLETED
Sep 21, 2026
Press release
Abivax Presents Business Updates and First Half 2026 Financial Results
Abivax Presents Business Updates and First Half 2026 Financial Results
Reddit
Recent posts
All social signals and their track records

SecBot reports

6 filings · 3 press releases · 1 bullish · 2 bearish · 1 mixed · 2 neutral
All ABVX filing & press-release reports (9)